Pfizer boss Jonathan Emms is set to become the new president of the ABPI from April 2014.
Emms, the current UK managing director of Pfizer, was recently announced as the new president of the ABPI, a role the life-long pharmaceutical worker describes as “an honour”.
Father-of-three Emms, who started his career in the pharmaceutical industry 24 years ago, worked with Glaxo before joining Pfizer in 1999. The self-confessed Manchester United fan has taken various roles during his 14 years with Pfizer, from sales and marketing leadership positions to work on the Continent establishing regional teams and offices. He was made UK managing director of the company in January 2012.
In a statement released on the ABPI website earlier this week, Emms said he was “immensely proud to work in an industry which makes such a positive difference to the health of millions of people” and was honoured to take on the leadership role with the ABPI “at such a crucial time”.
Stephen Whitehead, chief executive of the ABPI, gave the incoming president a glowing endorsement: “I have no doubt that Jonathan will provide strong leadership to the ABPI and the industry as a whole”, he said, suggesting this was a “significant time for a new President as we enter a new pricing era.”
The ABPI is currently developing a new voluntary pricing scheme, which will begin in 1 January 2014. The task of developing and embedding the new scheme will fall to Emms when he takes over from outgoing president Deepak Khanna in April.
Emms will serve as president for a 12-month period, with the option of standing for re-election next year.